Inclusion criteria:  ≥1 Healthcare Common Procedure Coding System (HCPCS) code (J code) or National Drug Code (NDC) for treatment with brolucizumab during the index period (date of earliest code = index date) ≥18 years old on the index date  ≥1 International Classification of Diseases, Clinical Modification-9/10 (ICD-9/10) code for wet AMD in the 36 months prior to or on the index date  Note: Off-label use of brolucizumab is not expected given payer access restrictions in the US ≥24 months of continuous enrollment prior to the index date ≥1 follow-up visit related to their wet AMD after the index date  Exclusion criteria:  Use of brolucizumab prior to 08-Oct-2019 (e.g. clinical trials) Unknown laterality of the index eye on the index date Patients with no data throughout the 12 months immediately prior to the index date